Evidence map›Paper›PMID 41914670›Full record

ArticleFuture oncology (London, England)2026

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.

Reinhard Dummer, Shahneen Sandhu, Wilson H Miller, Marcus O Butler, Matthew H Taylor, Lucie Heinzerling, Christian U Blank, Eva Muñoz Couselo, Howard A Burris, Michael A Postow and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Reinhard DummeraDepartment of Dermatology, Skin Cancer Unit, University Hospital Zurich, Zurich, Switzerland.
Shahneen SandhubSir Peter MacCallum Cancer Department of Oncology, University of Melbourne, Melbourne, Australia.
Wilson H MillercLady Davis Institute and Segal Cancer Centre, Jewish General Hospital, Departments of Medicine and Oncology, McGill University, Montreal, Canada.
Marcus O ButlerdPrincess Margaret Cancer Centre, University Health Network, Departments of Medicine and Immunology, University of Toronto, Toronto, Canada.
Matthew H TayloreEarle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.
Lucie HeinzerlingfDepartment of Dermatology and Allergy, University Hospital, Ludwig Maximilian University, Munich, Germany.
Christian U BlankgDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Eva Muñoz CouselohDepartment of Medical Oncology, Melanoma and Other Skin Cancers Unit, Vall d'Hebron Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Howard A BurrisiSarah Cannon Research Institute, Nashville, TN, USA.
Michael A PostowjDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
Bartosz ChmielowskikJonsson Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Mark R MiddletonlNIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK; Department of Oncology, University of Oxford, Oxford, UK; Early Phase Clinical Trials Unit, Cancer & Haematology Centre, Churchill Hospital, Oxford, UK.
Carola BerkingmDepartment of Dermatology, Uniklinikum Erlangen, CCC Erlangen - EMN, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
Jessica C HasselnHeidelberg University, Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, Germany.
Anja Heike GesierichoDepartment of Dermatology, Venerology and Allergology, University Hospital Würzburg, Würzburg, Germany.
Cornelia MauchpDepartment of Dermatology and Venereology, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
Joseph F KlehaqPfizer, New York, NY, USA.
Anna PollirPfizer, Milan, Italy.
Allison S HarneysPfizer Boulder Research Unit, Boulder, CO, USA.
Alessandra di PietrorPfizer, Milan, Italy.
Paolo A AsciertotMelanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

binimetinibBRAF V600encorafenibLOGIC 2melanomaplain language summarythird drug

Identifiers

PMID41914670
PMCPMC13064556

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.